QSAM Biosciences, Inc. is committed to advancing the fight against cancer through discovery, development and delivery of effective treatment options to adult and pediatric patients. We aim to develop targeted therapeutic radiopharmaceuticals as safer and more efficacious alternatives to current treatment modalities in order to address large unmet medical needs and underserved patient populations. To that end, QSAM is developing a next-generation radiotherapeutic platform to serve multiple indications.
Our lead technology, Samarium-153 DOTMP (CycloSam®), is a clinical-stage bone-seeking radiopharmaceutical designed to safely and precisely deliver targeted radiation to tumors in the skeletal system. CycloSam® delivers the beta-emitting radioisotope, Samarium-153, to areas of rapid bone formation through a chelant, DOTMP, emitting a potent yet controlled dose of radiation treatment directly to the tumor environment while minimizing radiation exposure to healthy tissue.
We believe improvements in formulation and manufacturing from a prior FDA-approved drug utilizing the same radioisotope has resulted in our drug candidate demonstrating significantly less impurities, lower costs and better availability. In early clinical testing, Samarium-153 DOTMP’s highly stable complex, short 46 hour half-life and low impurity profile, is demonstrating meaningful pain palliation effects in patients with metastatic prostate and breast cancer, and in future studies, may demonstrate disease modifying results in primary bone cancer patients, including children and young adults suffering from Osteosarcoma.